4F9M image
Entry Detail
PDB ID:
4F9M
Title:
Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2012-05-19
Release Date:
2012-08-08
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.25
R-Value Work:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Peroxisome proliferator-activated receptor gamma
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:peptide from Nuclear receptor coactivator 1
Chain IDs:B (auth: C)
Chain Length:15
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Synthesis and biological evaluation of novel (-)-cercosporamide derivatives as potent selective PPARg modulators
Eur.J.Med.Chem. 54 522 533 (2012)
PMID: 22727448 DOI: 10.1016/j.ejmech.2012.05.040

Abstact

Selective peroxisome proliferator-activated receptor gamma (PPARγ) modulators are expected to be a novel class of drugs improving plasma glucose levels without PPARγ-related adverse effects. As a continuation of our studies for (-)-Cercosporamide derivatives as selective PPARγ modulators, we synthesized substituted naphthalene type compounds and identified the most potent compound 15 (EC(50) = 0.94 nM, E(max) = 38%). Compound 15 selectively activated PPARγ transcription and did not activate PPARα and PPARδ. The potassium salt of compound 15 showed a high solubility and a good oral bioavailability (58%). Oral administration of the potassium salt remarkably improved the plasma glucose levels of female Zucker diabetic fatty rats at 1 mg/kg. Moreover, it did not cause a plasma volume increase or a cardiac enlargement in Wistar-Imamichi rats, even at 100 mg/kg.

Legend

Protein

Chemical

Disease

Primary Citation of related structures